Pharma

Backed by Bessemer Venture Partners, Stride Ventures and Tanmay Bhat, the company was valued at nearly Rs 1,000 crore and plans to expand categories and omnichannel distribution

SC scrutiny highlights the need for statutory backing, clear enforcement and patient-focused regulation

Sun Pharmaceutical Industries has said its board of directors has approved a proposal to raise funds of up to Rs 10,000 crore through the issuance of non-convertible debentures (NCDs). The decision was taken at a meeting of the company's Board of Directors held on October 12, Sun Pharma said in a regulatory filing late on Monday evening. The board approved the issuance of listed, rated, unsecured, redeemable NCDs on a private placement basis in one or more tranches and/or series for an aggregate amount not exceeding Rs 10,000 crore. The company said that disclosures required under Regulation 30 of the Sebi (Listing Obligations and Disclosure Requirements) Regulations, 2015, will be made at an appropriate stage upon the issuance or allotment of the debentures. Separately, the company announced that Gautam Doshi has resigned as a Non-Executive, Independent Director with immediate effect, citing personal reasons. Consequent upon his resignation, he has also ceased to hold positions on

Move could cut MRPs by up to 70%, save patients ₹2,500 crore annually; comes amid SC scrutiny of high mark-ups

The combined Maharashtra business is expected to generate around ₹500 crore in revenue this year, with plans to establish a presence in every district headquarters

Funding will be part of a new track under the PRIP scheme exclusively for start-ups and MSMEs at the initial research stage, with assistance of up to ₹50 crore per project

Pharma sector needs a supportive environment

The company's board approved the transaction on Monday, following which Novartis India executed an asset purchase agreement and trademark assignment deeds with Pfizer Inc and Pfizer Products Inc

Novartis doubles down on innovation in India, eyeing R&D, clinical trials and a stronger regulatory ecosystem while moving away from traditional generics

The market recorded sales of Rs 23,193 crore in July, with cardiac and anti-diabetic therapies posting double-digit growth and four leading segments accounting for 46.6 per cent

Supriya Lifescience said proceedings were initiated against the personnel of the company under the NDPS Act, 1985 for a procedural lapse for a single export transaction of an identified producer.

Zydus Lifesciences and Sri Lanka's Sunshine Healthcare on Friday announced the setting up of a joint venture with an investment commitment of over USD 20 million to establish a pharmaceutical manufacturing facility in the island nation. The company has entered into a share subscription and shareholders' agreement (SSSHA) with Sunshine Healthcare Lanka Ltd (Sunshine) and Zydus Sunshine Lifesciences (Pvt) Ltd (Zydus Sunshine), Zydus Lifesciences said in a regulatory filing. Under the SSSHA, Zydus Lifesciences will subscribe 50 per cent of the total paid-up equity share capital of Zydus Sunshine for up to USD 5 million in one or more tranches, it added. Zydus Sunshine will set up a manufacturing facility in Horana Export Processing Zone in Sri Lanka to manufacture pharmaceutical products, which will strengthen local production and reduce import dependence, the filing said. This will improve access to high-quality medicines while supporting national supply chain resilience, it ...

HRV Pharma owns drug master files and customer relationships while outsourcing production to 53 manufacturing partners, aiming to scale without owning factories

For decades, India excelled at making affordable generic medicines. But creating a brand-new drug from scratch remained a rare achievement. Now, Wockhardt has made history with Zaynich

Says higher import duties, regulatory hurdles have made chemo drugs' production unviable

Indian pharmaceutical companies are investing in specialty drugs, biosimilars and local manufacturing in the US despite a near 10 per cent fall in exports in FY26

HAB Pharmaceuticals aims to scale operations and expand globally after merging with Signature Phytochemical Industries through a slump sale deal

India is in the race for a new class of weight-loss drugs, but the question is: Will they be affordable?

Sun Pharma sees its Organon acquisition as a platform to expand globally, boost in-licensing, and improve long-term efficiencies through a stronger commercial front-end

In this exclusive conversation with Business Standard, Sujit Paul, CEO of Zota Healthcare and the driving force behind DavaIndia, shares bold views on the future of healthcare